Table Info

Table 2.

Seizure monthly rate evolution

ID	SMSR	M1	M2	M3	TAR1	M4	M5	M6	TAR2	M7	M8	M9	TAR3	SR (%)
P-01	13	21	13	27	20.33	9	23	9	13.67	9	6	23	12.67	2.56
P-02	4	0	0	0	0	0	0	0	0	1	0	0	0.33	91.67
P-03	7	4	7	4	5	6	5	10	7	5	0	3	2.67	61.9
P-04	174	173	49	46	89.33	45	52	51	49.33	31	30	21	27.33	84.29
P-05	5	2	3	1	2	1	0	2	1	3	2	0	1.67	66.67
P-06	4	1	1	1	1	2	0	1	1	0	0	0	0	100
P-07	5	0	0	0	0	0	0	0	0	0	0	0	0	100
P-08	58	34	34	40	36	37	21	28	28.67	-	-	-	-	50.57
P-09	4	0	0	0	0	0	2	0	0.67	-	-	-	-	83.33
P-10	4	0	1	0	0.33	0	0	0	0	-	-	-	-	100
P-11	39	38	18	18	24.67	22	28	17	22.33	-	-	-	-	42.74
P-12	12	8	2	3	4.33	2	0	1	1	-	-	-	-	91.67
P-13	9	1	5	4	3.33	4	3	4	3.67	-	-	-	-	59.26
P-14	12	8	6	3	5.67	2	4	4	3.33	-	-	-	-	72.22
P-15	163	98	67	150	105	75	95	72	80.67	-	-	-	-	50.51
P-16	6	5	12	5	7.33	0	7	4	3.67	-	-	-	-	38.89
P-17	65	30	19	6	18.33	6	17	3	8.67	-	-	-	-	86.67
P-18	170	126	146	39	103.67	32	61	78	57	-	-	-	-	66.47

The MSR behavior throughout the pilot trial. ID: subject identification; SMSR: starting seizure monthly rate; M1, …, M9: month 1 until 9; TAR: trimestral average rate; SR: seizure rate reduction in percent; -: not computed

Declarations

Author contributions

RIGF: Conceptualization, Investigation, Writing—original draft. VRV: Conceptualization, Investigation, Validation. JGPB, EVR, and LPH: Conceptualization, Investigation. ASS and JGG: Validation, Supervision. JLHC: Conceptualization, Writing—review & editing. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

The pilot trial carried out was approved by the Cuban regulatory body for medical technology and the ethics committees of the Cuban Center for Neuroscience and the Institute of Neurology and Neurosurgery of Havana. Also, the trail complies with Declaration of Helsinki.

Consent to participate

Informed consent to participate in the study was obtained from all participants.

Consent to publication

Not applicable.

Availability of data and materials

The datasets for this manuscript are not publicly available because of the internal policy of the Cuban regulatory body. Requests for accessing the datasets should be directed to [Rene Ivan Gonzalez-Fernandez, rigf58@yahoo.com].

Funding

Not applicable.

Copyright

References

Epilepsy: a public health imperative [Internet]. World Health Organization; c2019 [cite 2023 Jan 2]. Available from: https://www.who.int/publications/i/item/epilepsy-a-public-health-imperative

Zangiabadi N, Ladino LD, Sina F, Orozco-Hernández JP, Carter A, Téllez-Zenteno JF. Deep brain stimulation and drug-resistant epilepsy: a review of the literature. Front Neurol. 2019;10:601. [DOI] [PubMed] [PMC]

Beghi E. The epidemiology of epilepsy. Neuroepidemiology. 2020;54:185–91. [DOI] [PubMed]

Oliveira TVHF, Francisco AN, Demartini Z Junior, Stebel SL. The role of vagus nerve stimulation in refractory epilepsy. Arq Neuropsiquiatr. 2017;75:657–66. [DOI] [PubMed]

Shan M, Mao H, Xie H, Gan Y, Wu D, Song J, et al. Vagus nerve stimulation for drug resistant epilepsy: clinical outcome, adverse events, and potential prognostic factors in a single center experience. J Clin Med. 2022;11:7536. [DOI] [PubMed] [PMC]

Zagon A, Kemeny AA. Slow hyperpolarization in cortical neurons: a possible mechanism behind vagus nerve simulation therapy for refractory epilepsy? Epilepsia. 2000;41:1382–9. [DOI] [PubMed]

Kim AY, Marduy A, de Melo PS, Gianlorenco AC, Kim CK, Choi H, et al. Safety of transcutaneous auricular vagus nerve stimulation (taVNS): a systematic review and meta-analysis. Sci Rep. 2022;12:22055. [DOI] [PubMed] [PMC]

von Wrede R, Surges R. Transcutaneous vagus nerve stimulation in the treatment of drug-resistant epilepsy. Auton Neurosci. 2021;235:102840. [DOI] [PubMed]

Bauer S, Baier H, Baumgartner C, Bohlmann K, Fauser S, Graf W, et al. Transcutaneous vagus nerve stimulation (tVNS) for treatment of drug-resistant epilepsy: a randomized, double-blind clinical trial (cMPsE02). Brain Stimul. 2016;9:356–63. [DOI] [PubMed]

10.

Rong P, Liu A, Zhang J, Wang Y, He W, Yang A, et al. Transcutaneous vagus nerve stimulation for refractory epilepsy: a randomized controlled trial. Clin Sci (Lond). 2014;[Epub ahead of print]. [DOI] [PubMed]

11.

Shraddha M, Onkar S. Vagus nerve stimulation market by product (implantable VNS devices, external VNS devices), by application (epilepsy, depression, others), by end user (hospitals, neurology clinics, others): global opportunity analysis and industry forecast, 2023–2032. Global: Life Sciences, Allied Market Research; 2023 Apr. Report No.: A03623. Contract No.: Q2024220406. Free sample.

12.

Stefan H, Kreiselmeyer G, Kerling F, Kurzbuch K, Rauch C, Heers M, et al. Transcutaneous vagus nerve stimulation (t-VNS) in pharmacoresistant epilepsies: a proof of concept trial. Epilepsia. 2012;53:e115–8. [DOI] [PubMed]

13.

Aihua L, Lu S, Liping L, Xiuru W, Hua L, Yuping W. A controlled trial of transcutaneous vagus nerve stimulation for the treatment of pharmacoresistant epilepsy. Epilepsy Behav. 2014;39:105–10. [DOI] [PubMed]

14.

Barbella G, Cocco I, Freri E, Marotta G, Visani E, Franceschetti S, et al. Transcutaneous vagal nerve stimulatio (t-VNS): an adjunctive treatment option for refractory epilepsy. Seizure. 2018;60:115–9. [DOI] [PubMed]

15.

He W, Jing X, Wang X, Rong P, Li L, Shi H, et al. Transcutaneous auricular vagus nerve stimulation as a complementary therapy for pediatric epilepsy: a pilot trial. Epilepsy Behav. 2013;28:343–6. [DOI] [PubMed]

16.

Gerges ANH, Williams EER, Hillier S, Uy J, Hamilton T, Chamberlain S, Hordacre B. Clinical application of transcutaneous auricular vagus nerve stimulation: a scoping review. Disabil Rehabil. 2024:1–31. [DOI] [PubMed]

17.

Song GF, Wang HY, Wu CJ, Li X, Yang FY. A retrospective study of transcutaneous vagus nerve stimulation for poststroke epilepsy. Medicine (Baltimore). 2018;97:e11625. [DOI] [PubMed] [PMC]

18.

Liu A, Rong P, Gong L, Song L, Wang X, Li L, et al. Efficacy and safety of treatment with transcutaneous vagus nerve stimulation in 17 patients with refractory epilepsy evaluated by electroencephalogram, seizure frequency, and quality of life. Med Sci Monit. 2018;24:8439–48. [DOI] [PubMed] [PMC]

19.

Redgrave J, Day D, Leung H, Laud PJ, Ali A, Lindert R, et al. Safety and tolerability of transcutaneous vagus nerve stimulation in humans; a systematic review. Brain Stimul. 2018;11:1225–38. [DOI] [PubMed]

20.

Jiakai HE, Jinling Z, Yu W, Shaoyuan LI, Jiliang F, Shuai Z, et al. Transcutaneous auricular vagus nerve stimulation would be an alternative to implantable cervical vagus nerve stimulation in some situation. J Tradit Chin Med. 2023;43:627–30. [DOI] [PubMed] [PMC]

21.

Sarma GRK, Sharma AR, John AT. Transcutaneous electrical stimulation of auricular branch of the vagus nerve effectively and rapidly modulates the EEG patterns in patients with possible electrographic status epilepticus. Epileptic Disord. 2023;25:500–9. [DOI] [PubMed]